试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2020-08-20
Treatment of Crohn's Disease With an Antibiotic Regimen Directed Against Mycobacterium Avium Paratuberculosis
编号:NCT00513552登记状态:入组前撤回企业 / 申办者:Medstar Health Research Institute
药物 / 成分:Rifabutin, Clarithromycin, and Clofazimine
登记的停止原因(原文):No patient
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2020-08-20
Radiation Therapy and Ixabepilone in Treating Patients With High-Risk Stage III Prostate Cancer After Surgery
编号:NCT01079793登记状态:入组前撤回企业 / 申办者:University of Texas Southwestern Medical Center
药物 / 成分:ixabepilone、adjuvant therapy、intensity-modulated radiation therapy
登记的停止原因(原文):Overlapping study, PI preferred to enroll in alternate trial.
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2020-08-20
Altered Chemotherapy Sequencing During Neoadjuvant Therapy for Patients With Stage II or III Rectal Adenocarcinoma
编号:NCT01302613登记状态:入组前撤回企业 / 申办者:University of Texas Southwestern Medical Center
药物 / 成分:Capecitabine、5-FU、Leucovorin、Oxaliplatin
登记的停止原因(原文):Drug shortage
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2020-08-20
Ixabepilone and SBRT For Metastatic Breast Cancer
编号:NCT01818999登记状态:入组前撤回企业 / 申办者:University of Texas Southwestern Medical Center
药物 / 成分:IXABEPILONE、STEREOTACTIC BODY RADIATION THERAPY
登记的停止原因(原文):low accrual
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2020-08-20
SAbR Plus Ipilimumab Plus Nivolumab in Metastatic Melanoma Patients
编号:NCT03126461登记状态:入组前撤回企业 / 申办者:University of Texas Southwestern Medical Center
药物 / 成分:SAbR、Ipilimumab、Nivolumab
登记的停止原因(原文):the project was never initiated and no participants were enrolled, it was closed permanently
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2020-08-20
Concentration-effect Relationship of Enoxaparin for Thromboembolic Prevention
编号:NCT04520620登记状态:入组前撤回企业 / 申办者:Centre Hospitalier Universitaire de Saint Etienne
药物 / 成分:Lovenox 40 MG in 0.4 mL Prefilled Syringe、Ultrasound of the lower limbs
登记的停止原因(原文):End of the COVID 19 epidemic in the region and decision to participate in a national study on the same subject (COVI-DOSE).
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2020-08-19
INCB053914 and Pomalidomide With Dexamethasone for Relapsed and/or Refractory Multiple Myeloma
编号:NCT04355039登记状态:入组前撤回企业 / 申办者:Medical College of Wisconsin
药物 / 成分:Pomalidomide、Dexamethasone、INCB053914 50 mg bis in die (BID)、INCB053914 65 mg BID
登记的停止原因(原文):Terminated for lack of funding.
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2020-08-19
iNOPulse for COVID-19
编号:NCT04398290登记状态:入组前撤回企业 / 申办者:Roger Alvarez
药物 / 成分:Inhaled nitric oxide (iNO)、Nitrogen gas、Oxygen gas
登记的停止原因(原文):IRB AND FDA REVIEWS DEFERRED
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2020-08-18
Probiotics for Girls With Recurring Urinary Tract Infections
编号:NCT00789464登记状态:入组前撤回企业 / 申办者:Baylor College of Medicine
药物 / 成分:Lactobacillus reuteri DSM 17938、trimethoprim/sulfamethoxazole
登记的停止原因(原文):Withdrawn by PI
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2020-08-18
A Study to Evaluate Multimodal Neuroimaging Parameters in Women With Postpartum Depression Who Are Receiving ZULRESSO™ (Brexanolone)
编号:NCT04273191登记状态:入组前撤回企业 / 申办者:Sage Therapeutics
药物 / 成分:Brexanolone
登记的停止原因(原文):Sage Therapeutics has decided not to proceed with this study at this time
查看官方原始记录 ↗